CTNeT - Dr. Geyer Presentation CPRIT 2012

765 views

Published on

Dr. Charles Geyer, Jr., President & CMO of the Statewide Clinical Trials Network of Texas (CTNeT) discusses CTNeT (Statewide Clinical Trials Network of Texas) and its role in Building Texas' Life Sciences Infrastructure; Getting the Most Promising Science to the Most People at the 2012 CPRIT Innovation in Cancer Conference

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
765
On SlideShare
0
From Embeds
0
Number of Embeds
7
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

CTNeT - Dr. Geyer Presentation CPRIT 2012

  1. 1. Building Texas’ Life Science Infrastructure Charles E. Geyer, Jr., MD President and CMOInnovations in Cancer Research and Prevention Conference CPRIT 2012
  2. 2. Creation of CTNeT CPRIT infrastructure grant established CTNeT to facilitate and coordinate the conduct of statewide clinical trials in cancer – Applied Science Main scientific tenets: • Conduct statewide, tissue-based and biomarker-driven clinical trials focused on advancing targeted, more personalized care for cancer • Collaborate closely with the CPRIT-funded Texas Cancer Research Biobank (TCRB) • Implement efficient and scalable cancer clinical trials model to rapidly develop, activate, conduct and analyze high quality clinical trials
  3. 3. Vision of CTNeT Improve access of Texans with cancers that are considered incurable to promising new cancer treatments by providing: • extensive genetic analyses of their tumors to identify targets of new drugs in development • statewide clinical trials of new drugs targeting genetic abnormalities identified as possible key drivers of their cancers • statewide clinical trials evaluating new drugs in rare malignancies including childhood cancers
  4. 4. Chronic Myeloid Leukemia
  5. 5. Chronic Myeloid LeukemiaTranslocation – Dominant Driver Gene Legend BCR-Abl fusion gene - 99%
  6. 6. Breast Cancer
  7. 7. Breast CancerAmplification – Dominant Driver Gene Legend HER2 Amplification - 15%
  8. 8. Lung Cancer
  9. 9. Lung CancerArray of Low Frequency Genetic Alterations Legend EGFR mutation - 14% KRAS mutation - 24% EML4-ALK translocation - 4% MET aberration - 15% KIF5B RET translocation - 2% BRAF mutation - 2%
  10. 10. Lung CancerClinical Trial Targeting MET Aberrant Disease Legend MET aberrations
  11. 11. Lung CancerClinical Trial Targeting MET Aberrant Disease Legend MET mutation or overexpression MET amplification
  12. 12. Lung CancerClinical Trial Targeting MET Aberrant Disease Legend MET mutation MET or overexpression amplification
  13. 13. Lung CancerClinical Trial Targeting KRAS Mutant Disease Legend KRAS mutation
  14. 14. Lung CancerClinical Trial Targeting KRAS Mutant Disease Legend KRAS mutation TS gene 1 wild TS gene 2 wild KRAS mutation TS gene 1 mutant TS gene 2 wild KRAS mutation TS gene 1 wild TS gene 2 mutant
  15. 15. Lung CancerClinical Trial Targeting KRAS Mutant Disease Legend KRAS mutation KRAS mutation KRAS mutation TS gene 1 wild TS gene 1 mutant TS gene 1 wild TS gene 2 wild TS gene 2 wild TS gene 2 mutant
  16. 16. Lung CancerTrial Targeting KIF5B RET Translocation Legend KIF5B RET translocation
  17. 17. KIF5B RET Inhibitor Clinical Trial
  18. 18. BRAF V600E Inhibitor Clinical Trial
  19. 19. Single Molecular Characterization Protocol
  20. 20. Molecular Characterization Infrastructure Tissue ResultsPatient Patient submitted reported CTNeTConsent Registration Members Tissue stored for All test results stored future research in data warehouse Communication with site for future CTNeT potential studies Biorepository Operations
  21. 21. Members of CTNeT BAYLOR COLLEGE of MEDICINE UT HEALTH SCIENCE CENTER AT HOUSTON CANCER CARE CENTERS of SOUTH TEXAS UT HEALTH SCIENCE CENTER at SAN ANTONIO CENTER for CANCER and BLOOD DISORDERS UT HEALTH SCIENCE CENTER AT TYLERMARY CROWLEY CANCER RESEARCH CENTER UT MD ANDERSON CANCER CENTER MEMORIAL HERMANN CANCER CENTER UT MEDICAL BRANCH at GALVESTON THE METHODIST HOSPITAL SYSTEM UT SOUTHWESTERN MEDICAL CENTER ONCOLOGY CONSULTANTS, PA TEXAS CHILDREN’S CANCER CENTER SCOTT & WHITE HEALTHCARE TEXAS ONCOLOGY SOUTH TEXAS ONCOLOGY HEMATOLOGY AT START CENTER TEXAS TECH HEALTH SCIENCES CENTER / COVENANT HEALTH SYSTEM
  22. 22. Initial Portfolio of Studies Tissue Procurement and Molecular Testing: • Procurement and Molecular Characterization of Existing FFPE Tumor Samples to Identify Biomarker-Based Cohorts of Patients as Potential Candidates for Clinical Trials (N=2,500)
  23. 23. Initial Portfolio of Studies Clinical Studies: • Phase II study of MET inhibition in previously treated NSCLC, SCCHN and TNBC with MET aberrations (N=72) Study Co-chairs - George R. Blumenschein, Jr., MD and Ana M. Gonzalez-Angulo, MD, MSc (MDACC) • Phase II study of FAK inhibition in KRAS mutant NSCLC (N=114) Study Co-chairs - David E. Gerber, MD and Pier Paolo Scaglioni, MD (UTSW) • Phase II study of RET inhibition in KIF5B-RET-positive adenocarcinoma of the lung (N=20) • Phase II study of BRAF inhibition in BRAF V600E mutant adenocarcinoma of the lung (N=40)
  24. 24. Initial Portfolio of Studies Clinical Studies (continued): • Phase II study of dual MEK1 and FLT3 inhibition in relapsed/refractory AML with FLT3 and/or RAS mutation (N=60) Study Co-chairs - Gautam Borthakur, MD and Jorge E. Cortes, MD (MDACC) • Phase I/II study of combination of anti-CD22 antibody- chemotherapy conjugate with lower-intensity chemotherapy in elderly patients with ALL (N=66) Study Chair – Hagop M Kantarjian, MD (MDACC) • A Phase II, Multicenter, Single-Arm Study of G-202 as Second- Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma (N=29) Study Chair - Devalingam Mahalingam, MD, PhD (CTRC at UTHSC San Antonio)

×